0 CHECKOUT

Lyme Disease - Pipeline Review, H1 2015

  • ID: 3112086
  • January 2015
  • 42 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Baxter International Inc.
  • LondonPharma Ltd
  • Valneva SE
  • VG Life Sciences, Inc.
  • MORE

Lyme Disease - Pipeline Review, H1 2015

Summary

This, ‘Lyme Disease - Pipeline Review, H1 2015’, provides an overview of the Lyme Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lyme Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lyme Disease and special features on late-stage and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Baxter International Inc.
  • LondonPharma Ltd
  • Valneva SE
  • VG Life Sciences, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Lyme Disease Overview
Therapeutics Development
Pipeline Products for Lyme Disease - Overview
Pipeline Products for Lyme Disease - Comparative Analysis
Lyme Disease - Therapeutics under Development by Companies
Lyme Disease - Therapeutics under Investigation by Universities/Institutes
Lyme Disease - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Lyme Disease - Products under Development by Companies
Lyme Disease - Products under Investigation by Universities/Institutes
Lyme Disease - Companies Involved in Therapeutics Development
Baxter International Inc.
LondonPharma Ltd
Valneva SE
VG Life Sciences, Inc.
Lyme Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
azithromycin gel - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lyme borreliosis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lyme disease vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lyme disease vaccine 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Lyme Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VGV-L - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VLA-15 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lyme Disease - Recent Pipeline Updates
Lyme Disease - Dormant Projects
Lyme Disease - Product Development Milestones
Featured News & Press Releases
Mar 07, 2012: Viral Genetics Submits Pre-IND Document For Lyme Disease Drug Candidate To FDA
Oct 21, 2008: Viral Genetics, Inc. Releases Initial Findings of Lyme Disease Study and Team Receives Positive Feedback at ILADS Conference, Study Model Potentially Applies to HIV/AIDS and Other Immune Based Diseases.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Lyme Disease, H1 2015
Number of Products under Development for Lyme Disease - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Lyme Disease - Pipeline by Baxter International Inc., H1 2015
Lyme Disease - Pipeline by LondonPharma Ltd, H1 2015
Lyme Disease - Pipeline by Valneva SE, H1 2015
Lyme Disease - Pipeline by VG Life Sciences, Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Lyme Disease Therapeutics - Recent Pipeline Updates, H1 2015
Lyme Disease - Dormant Projects, H1 2015
Lyme Disease - Dormant Projects (Contd..1), H1 2015

List of Figures
Number of Products under Development for Lyme Disease, H1 2015
Number of Products under Development for Lyme Disease - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Baxter International Inc.
LondonPharma Ltd
Valneva SE
VG Life Sciences, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.